Actively Recruiting
Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis
Led by InventisBio Co., Ltd · Updated on 2025-12-09
390
Participants Needed
1
Research Sites
96 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a randomized, double-blind, placebo-controlled multicenter clinical trial targeting subjects with moderate to severe plaque psoriasis.
CONDITIONS
Official Title
Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily agrees to participate and signs informed consent
- Diagnosed with plaque psoriasis suitable for systemic treatment and stable for at least 6 months
- Psoriatic body surface area of 10% or more, Physician Global Assessment score of 3 or higher, and Psoriasis Area and Severity Index score of 12 or higher at screening
- Hematology, blood chemistry, and urinalysis tests are basically normal
You will not qualify if you...
- Diagnosed with erythrodermic, pustular, guttate, reverse, or drug-induced psoriasis
- Presence of other skin lesions like eczema that affect treatment evaluation
- History or current infection of herpes zoster or herpes simplex during screening
- History of tuberculosis, active or latent tuberculosis, or suspected tuberculosis infection
- Any other condition deemed unsuitable by the investigator for study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University People's Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
Research Team
N
Nan Tang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here